ResearcherMayo ClinicActive in the last 2 years

Osama M. Mosalem

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3779-185X; OpenAlex author ID A5076737381. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper

Papers 2

Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years. Co-author DOI 10.1080/13543784.2025.2473698 ↗
Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Clinical Trials. First author DOI 10.2147/ceg.s390655 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Hani M. Babiker · 2 shared papers, 2024–2025 · strength 0.62
- Paper Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years. DOI 10.1080/13543784.2025.2473698 ↗
- Paper Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Cli… DOI 10.2147/ceg.s390655 ↗
Ahmed Adel Fouad Abdelhakeem · 1 shared paper, 2025 · strength 0.37
- Paper Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years. DOI 10.1080/13543784.2025.2473698 ↗
Nayef Hikmat Abdel-Razeq · 1 shared paper, 2025 · strength 0.37
- Paper Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years. DOI 10.1080/13543784.2025.2473698 ↗
Mitesh J. Borad · 1 shared paper, 2024 · strength 0.26
- Paper Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Cli… DOI 10.2147/ceg.s390655 ↗
Robin John Lester Imperial · 1 shared paper, 2024 · strength 0.26
- Paper Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Cli… DOI 10.2147/ceg.s390655 ↗
Nguyen H. Tran · 1 shared paper, 2024 · strength 0.26
- Paper Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Cli… DOI 10.2147/ceg.s390655 ↗
Umair Majeed · 1 shared paper, 2024 · strength 0.26
- Paper Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Cli… DOI 10.2147/ceg.s390655 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.